Mechanism of Action
Tachykinin Receptor Activation
Eledoisin activates mammalian tachykinin receptors (NK1, NK2, NK3) with varying affinity. It has highest affinity for NK1 receptors, which are Gq-coupled GPCRs that stimulate phospholipase C, IP3 production, and intracellular calcium release. NK1 activation in vascular smooth muscle causes relaxation (vasodilation), while activation in intestinal smooth muscle causes contraction.
Salivary and Secretory Stimulation
Eledoisin is a potent stimulator of salivary gland secretion and has been used as an experimental tool to study exocrine secretion. It activates acinar cell receptors to increase fluid and protein secretion. This secretagogue activity in salivary glands was one of the earliest properties characterized after its isolation.
Research Summary
Historical Significance
PreclinicalEledoisin was isolated by Erspamer in 1962 and was among the first peptides of the tachykinin family to be chemically characterized. Its discovery stimulated the search for mammalian tachykinins and directly led to the characterization of the tachykinin consensus C-terminal sequence. Eledoisin remains an important pharmacological tool for tachykinin receptor research.
Dry Eye and Exocrine Disorders
PreclinicalEledoisin has been investigated as a topical agent for dry eye disease due to its ability to stimulate lacrimal and mucin secretion via NK1 activation in conjunctival goblet cells. Preclinical models show increased tear production and mucin secretion. Early clinical exploratory studies in dry eye were conducted in Italy.
Calculate your Eledoisin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Salivary secretion | 0.1-1 nmol/kg IV | Single | Intravenous bolus |
| NK receptor pharmacology | 1-100 nM | Single | Organ bath / cell assay |
Research and historical use. Not used therapeutically.
Interactions
Safety Profile
Eledoisin causes vasodilation, hypotension, and smooth muscle contraction in vivo. Intravenous administration can cause significant blood pressure drops due to systemic vasodilation. Topical ophthalmic use at low concentrations appears safer. No established human therapeutic dosing; primarily used as a research tool.
References
- [1]Erspamer V and Anastasi A (1962). Structure and pharmacological actions of eledoisin, the active endecapeptide of the posterior salivary glands of Eledone. Experientia, 18(2), 58-59.
- [2]Lecci A et al. (2006). The eledoisin-related peptide (ERP) and its relevance to dry eye. Neuropeptides, 40(3), 177-190.